Evidence map›Paper›PMID 40628697›Full record

ArticleNature communications2025

In silico genomic surveillance by CoVerage predicts and characterizes SARS-CoV-2 variants of interest.

Katrina Norwood, Zhi-Luo Deng, Susanne Reimering, Gary Robertson, Mohammad-Hadi Foroughmand-Araabi, Sama Goliaei, Martin Hölzer, Frank Klawonn, Alice C McHardy

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katrina Norwood *Computational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0009-0000-3593-0628
Zhi-Luo Deng *Computational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Susanne Reimering *Computational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Gary RobertsonComputational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Mohammad-Hadi Foroughmand-AraabiComputational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Sama GoliaeiComputational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Martin HölzerGenome Competence Center (MF1), Robert Koch Institute, Berlin, Germany.ORCID http://orcid.org/0000-0001-7090-8717
Frank KlawonnBiostatistics, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0000-0001-9613-182X
Alice C McHardyComputational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany. amc14@helmholtz-hzi.de.ORCID http://orcid.org/0000-0003-2370-3430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapidly evolving viral pathogens such as SARS-CoV-2 continuously accumulate amino acid changes, some of which affect transmissibility, virulence or improve the virus' ability to escape host immunity. Since the beginning of the SARS-CoV-2 pandemic, multiple lineages with concerning phenotypic alterations, so-called Variants of Concern (VOCs), have emerged and risen to predominance. To optimize public health management and ensure the continued efficacy of vaccines, the early detection of such variants is essential. Therefore, large-scale viral genomic surveillance programs have been initiated worldwide, with data being deposited in public repositories in a timely manner. However, technologies for their continuous interpretation are lacking. Here, we describe the CoVerage system ( www.sarscoverage.org ) for viral genomic surveillance, which continuously predicts and characterizes emerging potential Variants of Interest (pVOIs) from country-wise lineage frequency dynamics, together with their antigenic and evolutionary alterations utilizing the GISAID viral genome resource. In a comprehensive assessment of VOIs, VUMs, and VOCs, we demonstrate how CoVerage can be used to swiftly identify and characterize such variants, with a lead time of almost three months relative to their WHO designation. CoVerage can facilitate the timely identification and assessment of future SARS-CoV-2 variants relevant for public health.

Indexed as

COVID-19Genome, ViralGenomicsSARS-CoV-2Computer SimulationHumansPhylogeny

Identifiers

PMID40628697
PMCPMC12238648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.